Mutation-specific downregulation of CFTR2 variants by gating potentiators
暂无分享,去创建一个
G. Lukács | Andrea Schnur | Haijin Xu | E. Matouk | S. Frenkiel | Yukari Kai | Radu G. Avramescu | G. Veit | Aurélien Bidaud-Meynard | R. Avramescu
[1] J. Jais,et al. Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators , 2017, Scientific Reports.
[2] L. Hoffman,et al. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections , 2017, American journal of respiratory and critical care medicine.
[3] S. Randell,et al. Pharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells , 2017, American journal of respiratory cell and molecular biology.
[4] D. Gadsby,et al. Molecular Structure of the Human CFTR Ion Channel , 2017, Cell.
[5] S. Agarwal,et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens , 2017, Nature Protocols.
[6] David Y. Thomas,et al. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor) , 2016, British journal of pharmacology.
[7] Garry R. Cutting,et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations , 2016, Molecular biology of the cell.
[8] G. Lukács,et al. Potentiators of Defective ΔF508–CFTR Gating that Do Not Interfere with Corrector Action , 2015, Molecular Pharmacology.
[9] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[10] Garry R. Cutting,et al. Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.
[11] D. Sheppard,et al. Chronic ivacaftor treatment: getting F508del-CFTR into more trouble? , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[12] N. Dokholyan,et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.
[13] G. Lukács,et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression , 2014, Science Translational Medicine.
[14] S. McColley,et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.
[15] M. Amaral,et al. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D‐CFTR , 2014, The Journal of physiology.
[16] S. Randell,et al. Breaking the in vitro alveolar type II cell proliferation barrier while retaining ion transport properties. , 2014, American journal of respiratory cell and molecular biology.
[17] Ewart A. C. Thomas,et al. A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor , 2014, PloS one.
[18] F. van Goor,et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[19] I. Jaspers,et al. Culturing of human nasal epithelial cells at the air liquid interface. , 2013, Journal of visualized experiments : JoVE.
[20] E. Major,et al. More on JC viremia in natalizumab-treated patients with multiple sclerosis. , 2013, The New England journal of medicine.
[21] George P Patrinos,et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.
[22] G. Lukács,et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.
[23] D. Murphy,et al. Ivacaftor in a G551D homozygote with cystic fibrosis. , 2013, The New England journal of medicine.
[24] G. Lukács,et al. Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia , 2012, Molecular biology of the cell.
[25] F. van Goor,et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[26] A S Verkman,et al. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.
[27] Chris Albanese,et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.
[28] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[29] P. Negulescu,et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.
[30] S. Willsie. Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation , 2011 .
[31] G. Lukács,et al. CFTR Folding Consortium: methods available for studies of CFTR folding and correction. , 2011, Methods in molecular biology.
[32] F. van Goor,et al. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. , 2011, Methods in molecular biology.
[33] A. Verkman,et al. CFTR-Adenylyl Cyclase I Association Responsible for UTP Activation of CFTR in Well-Differentiated Primary Human Bronchial Cell Cultures , 2010, Molecular biology of the cell.
[34] N. Pedemonte,et al. Influence of cell background on pharmacological rescue of mutant CFTR. , 2010, American journal of physiology. Cell physiology.
[35] P. Negulescu,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[36] G. Lukács,et al. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic , 2009, The Journal of cell biology.
[37] J. Riordan,et al. CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.
[38] C. Ehrhardt,et al. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o- , 2006, Cell and Tissue Research.
[39] S. Rowe,et al. Cystic fibrosis. , 2005, The New England journal of medicine.
[40] Milan Macek,et al. Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.
[41] Y. Jan,et al. A New ER Trafficking Signal Regulates the Subunit Stoichiometry of Plasma Membrane KATP Channels , 1999, Neuron.
[42] T. Hwang,et al. Genistein potentiates wild-type and delta F508-CFTR channel activity. , 1997, The American journal of physiology.
[43] M. Welsh,et al. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.
[44] M. Welsh,et al. Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. , 1992, The Journal of clinical investigation.
[45] C. Higgins,et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. , 1991, Proceedings of the National Academy of Sciences of the United States of America.